Suppr超能文献

直肠指检在接受主动监测的前列腺癌人群中的效用。

Utility of digital rectal examination in a population with prostate cancer treated with active surveillance.

作者信息

Herrera-Caceres Jaime O, Wettstein Marian S, Goldberg Hanan, Toi Ants, Chandrasekar Thenappan, Woon Dixon T S, Ahmad Ardalan E, Sanmamed-Salgado Noelia, Alhunaidi Omar, Ajib Khaled, Nason Gregory, Tan Guan Hee, Fleshner Neil, Klotz Laurence

机构信息

Division of Urology, Department of Surgical Oncology, University of Toronto and University Health Network, Toronto, ON, Canada.

Department of Medical Imaging, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada.

出版信息

Can Urol Assoc J. 2020 Sep;14(9):E453-E457. doi: 10.5489/cuaj.6341.

Abstract

INTRODUCTION

Digital rectal examination (DRE) is part of the clinical evaluation of men on active surveillance (AS). The purpose of the present study is to analyze the value of DRE as a predictor of upgrading in a population of men with prostate cancer (PCa) treated with AS.

METHODS

We used the prostate biopsy (PBx) database from an academic center, including PBx from 2006-2018, and identified 2029 confirmatory biopsies (CxPBx) of men treated with AS, of which 726 men had both diagnostic (initial) and CxPBx information available. We did a descriptive analysis and evaluated sensitivity, specificity, and predictive values of DRE for the detection of clinically significant PCa (csPCa). Multivariable regression analysis was done to identify predictors of csPCa. The primary outcome was to evaluate DRE as a predictor of the presence of csPCa at CxPBx.

RESULTS

Among the 2029 patients with a CxPBx, 75% had PCa, and of these, 30.3% had upgrading to International Society of Urologic Pathologists (ISUP) grade ≥2. Thirteen percent of men had a suspicious DRE (done by their treating physician). Sensitivity, specificity, negative and positive predictive values of DRE to detect csPCa were best with a prostate-specific antigen (PSA) <4 ng/ml (27%, 88%, 31%, and 87%, respectively). A suspicious DRE at CxPBx, particularly if the DRE at diagnosis was negative, was a predictor of csPCa (odds ratio [OR] 2.34, p=0.038). The main limitation of our study is the retrospective design and the lack of magnetic resonance imaging.

CONCLUSIONS

We believe DRE should still be used as part of AS and can predict the presence of csPCa, even with low PSA values. A suspicious nodule on DRE represents a higher risk of upgrading and should prompt further assessment.

摘要

引言

直肠指检(DRE)是对接受主动监测(AS)的男性进行临床评估的一部分。本研究的目的是分析在接受AS治疗的前列腺癌(PCa)男性人群中,DRE作为升级预测指标的价值。

方法

我们使用了一个学术中心的前列腺活检(PBx)数据库,包括2006年至2018年的PBx,并确定了2029例接受AS治疗男性的确诊活检(CxPBx),其中726名男性同时有诊断性(初始)和CxPBx信息。我们进行了描述性分析,并评估了DRE对检测临床显著前列腺癌(csPCa)的敏感性、特异性和预测价值。进行多变量回归分析以确定csPCa的预测因素。主要结果是评估DRE作为CxPBx时csPCa存在的预测指标。

结果

在2029例有CxPBx的患者中,75%患有PCa,其中30.3%升级为国际泌尿病理学会(ISUP)≥2级。13%的男性DRE可疑(由其主治医生进行)。当前列腺特异性抗原(PSA)<4 ng/ml时,DRE检测csPCa的敏感性、特异性、阴性和阳性预测值最佳(分别为27%、88%、31%和87%)。CxPBx时DRE可疑,特别是如果诊断时DRE为阴性,则是csPCa的预测因素(优势比[OR] 2.34,p = 0.038)。我们研究的主要局限性是回顾性设计和缺乏磁共振成像。

结论

我们认为DRE仍应作为AS的一部分使用,即使PSA值较低时也能预测csPCa的存在。DRE上可疑结节代表升级风险较高,应促使进一步评估。

相似文献

3
Digital Rectal Examination in Stockholm3 Biomarker-based Prostate Cancer Screening.
Eur Urol Open Sci. 2022 Aug 29;44:69-75. doi: 10.1016/j.euros.2022.08.006. eCollection 2022 Oct.
4
Negative Multiparametric Magnetic Resonance Imaging for Prostate Cancer: What's Next?
Eur Urol. 2018 Jul;74(1):48-54. doi: 10.1016/j.eururo.2018.03.007. Epub 2018 Mar 19.
9
Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
Eur Urol Oncol. 2019 Nov;2(6):664-669. doi: 10.1016/j.euo.2018.11.009. Epub 2018 Dec 14.

本文引用的文献

2
Active Surveillance Magnetic Resonance Imaging Study (ASIST): Results of a Randomized Multicenter Prospective Trial.
Eur Urol. 2019 Feb;75(2):300-309. doi: 10.1016/j.eururo.2018.06.025. Epub 2018 Jul 13.
3
Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018.
Eur Urol. 2018 Sep;74(3):357-368. doi: 10.1016/j.eururo.2018.06.008. Epub 2018 Jun 22.
4
MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis.
N Engl J Med. 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18.
7
Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study.
Lancet. 2017 Feb 25;389(10071):815-822. doi: 10.1016/S0140-6736(16)32401-1. Epub 2017 Jan 20.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验